Key Takeaways
- SHINE Technologies, based in Janesville, Wisconsin, is constructing a fusion‑energy facility to produce the medical isotope molybdenum‑99 (Mo‑99).
- The U.S. Department of Energy’s Office of Energy Dominance Financing awarded SHINE a $263 million loan to build the new production plant.
- Mo‑99 is the parent isotope of technetium‑99m, which is used in imaging to diagnose cancer, heart disease, and other conditions.
- Currently, most Mo‑99 is made overseas in aging fission reactors; the isotope decays quickly, causing up to one‑third loss during transport to the U.S.
- SHINE’s approach uses deuterium‑tritium fusion to generate neutrons, a cleaner and safer alternative to fission‑based production.
- The company is also applying its fusion technology to produce lutetium‑177 for therapeutic uses and envisions future applications in clean‑energy generation.
Project Overview and Funding
SHINE Technologies announced earlier this year that it has secured a $263 million loan from the U.S. Department of Energy’s Office of Energy Dominance Financing. The funds are earmarked for the construction of a new facility in Janesville dedicated to producing molybdenum‑99 (Mo‑99) through nuclear fusion. This investment underscores the federal government’s interest in establishing a domestic, reliable source of critical medical isotopes while advancing fusion technology.
Medical Importance of Mo‑99
Molybdenum‑99 serves as the parent isotope for technetium‑99m, the workhorse of nuclear medicine imaging. When bound to pharmaceuticals, Tc‑99m emits gamma rays that special cameras can detect, allowing clinicians to visualize blood flow in the heart, locate tumors, and assess disease progression. Greg Piefer, SHINE’s CEO, explained that the isotopes “attach themselves to drugs so that health care workers can see how the medicine is working in the body,” highlighting their indispensable role in both diagnosis and staging of conditions such as cancer and heart disease.
Supply Chain Vulnerabilities Abroad
Presently, the majority of global Mo‑99 originates from overseas fission reactors located in countries like Australia and South Africa. David Dick, a clinical professor of radiology at the University of Iowa’s Carver College of Medicine, noted that the isotope’s short half‑life means it deteriorates rapidly in transit, with up to a third of the original quantity lost before reaching U.S. hospitals. Because Mo‑99 cannot be stockpiled for extended periods, medical centers require weekly deliveries of fresh generators, making any disruption in the supply chain immediately impactful.
Aging Fission Infrastructure
The overseas facilities that produce Mo‑99 rely on traditional fission nuclear energy, many of which are operating well beyond their designed lifespans. As these plants age, they experience more frequent shutdowns for maintenance and repairs, exacerbating supply bottlenecks. Dick described the situation as a “dying supply chain,” where declining output coincides with rising demand for isotopes, creating a precarious imbalance that threatens consistent patient care.
Fusion Versus Fission: The Technological Shift
Nuclear fission generates energy by splitting heavy atomic nuclei, a process that produces long‑lived radioactive waste requiring careful disposal. In contrast, fusion combines light isotopes—such as deuterium and tritium—releasing neutrons and energy without the same volume of hazardous by‑products. Piefer emphasized that SHINE’s fusion method uses these light isotopes to achieve “the easiest” fusion reactions at comparatively low temperatures, capturing the emitted neutrons to transmute target materials into Mo‑99. He argued that fusion is “a much cleaner process” and ultimately safer because it avoids the problematic waste streams associated with fission.
Environmental and Safety Advantages of Fusion
Because fusion does not generate the high‑level actinide‑rich waste, the radiological footprint of SHINE’s facility is markedly smaller than that of a fission plant. The process also eliminates the risk of meltdown scenarios linked to uncontrolled fission chain reactions. By producing neutrons on‑demand and immediately using them to create isotopes, SHINE minimizes the inventory of radioactive material on site, enhancing overall safety for workers and the surrounding community.
Economic Context and Policy Drivers
Historically, private investment in new fission facilities has been limited due to high capital costs and the absence of substantial subsidies. As overseas fission reactors age and retire, the economic case for building new, domestic fission plants remains weak. SHINE’s fusion approach, supported by the DOE loan, offers a pathway to bypass those financial barriers while addressing the looming isotope shortage. The funding reflects a strategic push to incentivize innovative technologies that can strengthen national security in medical supply chains.
Growing Demand for Diagnostic and Therapeutic Isotopes
Beyond diagnostic imaging, there is expanding therapeutic use of isotopes such as lutetium‑177, which delivers targeted radiation to cancer cells. Piefer noted that demand is rising on both fronts, driving a global need for new neutron sources capable of producing a variety of medical isotopes efficiently. SHINE’s fusion platform is designed to be flexible, enabling the production of multiple isotopes from a single neutron‑generation core, thereby positioning the company to meet diverse clinical requirements.
Additional Facility: Lutetium‑177 Production
In parallel with the Mo‑99 project, SHINE already operates a separate fusion‑based facility in Janesville aimed at producing lutetium‑177. This isotope is used in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors and certain prostate cancers. By leveraging the same fusion neutron source, SHINE demonstrates the scalability of its technology across different isotopic applications, reinforcing the economic viability of a multi‑purpose fusion hub.
Founder’s Background and State Support
Greg Piefer earned his nuclear engineering degree from the University of Wisconsin‑Madison. He credited the state with actively working to keep his company in Wisconsin as he developed the fusion technology, citing local incentives, workforce talent, and a collaborative research ecosystem. Piefer’s long‑term vision extends beyond medical isotopes; he hopes to adapt SHINE’s fusion expertise toward clean‑energy generation, potentially contributing to decarbonization efforts while maintaining a strong foothold in the medical isotope market.
Conclusion and Outlook
SHINE Technologies’ endeavor to build a fusion‑driven Mo‑99 production facility represents a convergence of national security, healthcare reliability, and clean‑energy innovation. By replacing aging overseas fission reactors with a domestic fusion source, the company aims to eliminate costly isotope losses, ensure timely weekly deliveries to hospitals, and reduce the environmental burden of radioactive waste. The $263 million DOE loan signals federal confidence in this approach, while the parallel development of lutetium‑177 showcases the platform’s versatility. As demand for both diagnostic and therapeutic isotopes continues to climb, SHINE’s fusion technology could become a cornerstone of a resilient, sustainable supply chain for nuclear medicine—and perhaps, in the future, a stepping stone toward broader fusion‑based energy solutions.